Stromedix inc

Author: crrl

August undefined, 2024

WebJun 3, 2011 · This study was previously posted by Stromedix, Inc. In April, 2014, sponsorship of the trial was transferred to Biogen. The study drug name was changed from STX-100 to BG00011 and the study number was changed from STX-003 to 203PF201, to align with sponsor conventions. WebFounder of Infinity Pharmaceuticals, Inc., DNX Corp., Biotechnology Innovation Organization and Shoreline Biosciences, Inc., Steven H. Holtzman is an American entrepreneur and businessperson who has been at the head of 6 different companies and currently is Chairman of Camp4 Therapeutics Corp., Chairman for Hangzhou Qihan Biotechnology Co. …

Stromedix, Inc. Receives FDA Orphan Drug Designation for STX

WebCloud-Based Solutions for Healthcare and Insurance. Stradix is a leader in the independent medical review and claims management process and offers a variety of services to meet … WebCompany Type For Profit. Contact Email [email protected]. Phone Number 617.674.8400. Stromedix will focus initially on chronic indications but plans to leverage … hot and cold katy

Management Team - Arrakis Therapeutics

WebApr 6, 2009 · May 20, 2011 updated by: Stromedix, Inc. Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA) WebSep 17, 2024 · The drug was originally developed by Stromedix, a biotech founded and ran by a former Biogen executive, Michael Gilman. Biogen paid $75 million upfront to acquire … WebJan 25, 2011 · The most recently filed 13Fs psychotherapie impuls

Stromedix, Inc. Receives FDA Orphan Drug Designation for STX ... - BioSpace

WebFeb 14, 2012 · From an investment viewpoint, Stromedix is a very good deal for us. It raised only $38M in equity capital over its five-year life. The $75M upfront secures a positive return prior to the Phase 2 IPF trial that the syndicate was committed to funding, but preserves upside potential should this study succeed. WebJul 1, 2012 · Overnight, Cambridge, Mass.-based Stromedix became the next poster child for the virtual biotech model, life science businesses built around a core group of founding executives. psychotherapie im wandelWebBiogen, Inc. 225 Binney Street, Cambridge, Massachusetts 02142 United States, (617) 679-2000 www.biogen.com Profile M&A Activity (8) M&A Connections (5) M&A Advisors (2) Analytics M&A Summary Buy vs Sell +6 Most Recent M&A M&A by Sector By Geo Top M&A Advisors Deal Values M&A Connections Company Summary SECTOR Life Science … hot and cold katy perry clean

"WebStromedix is based out of Cambridge. The firm last filed a Form D notice of exempt offering of securities on 2011-01-25. The notice included securities offered of Debt Summary … " - Stromedix inc

Stromedix inc

Biogen to acquire developer of fibrosis treatments Reuters

WebApr 13, 2024 · As of April 2024, the average rent price in Sault Ste. Marie, ON for a 2 bedroom apartment is $1400 per month. Sault Ste. Marie average rent price is below the … WebTim Rice - Director Program Leadership and Management - Biogen Idec LinkedIn Tim Rice Director Program Management at Stromedix, Inc. Cambridge, Massachusetts, United States 67 connections...

Did you know?

WebFeb 14, 2012 · Stromedix is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. … WebFeb 14, 2012 · (Reuters) - Biogen Idec Inc BIIB.O has agreed to acquire Stromedix Inc, a privately held company developing treatments for fibrosis and organ failure, for $75 million cash and additional...

WebSTROMEDIX, INC. is a Delaware Corporation filed on June 8, 2006. The company's File Number is listed as 4172146. The Registered Agent on file for this company is … WebAug 31, 2010 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, …

WebFeb 17, 2012 · Biogen Idec ( BIIB ) recently signed a deal to acquire privately-held biotech company, Stromedix, Inc. With this acquisition, Biogen will gain access. WebComing off a year in which its earnings topped $5 billion, drugmaker Biogen Idec Inc. has struck a deal to pay $75 million — and possibly much more — for privately owned Stromedix Inc. and its ...

WebBrand New. Approach to Medicine. A worry-free process customized just for you. Combining Pain Management and Regenerative Medicine. For Orthopedic, Neurodegenerative, …

WebSTROMEDIX, INC. is a Massachusetts Foreign Corporation filed on February 28, 2007. The company's File Number is listed as 000945705. The Registered Agent on file for this … hot and cold katy perry just danceWebFeb 1, 2007 · Stromedix, Inc., is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. Stromedix's investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and Frazier Healthcare. psychotherapie in ausbildung piaWebStromedix Inc. Jun 2007 - Mar 2012 4 years 10 months. Cambridge, MA Privately held biotechnology company focused on innovative therapies for fibrosis and organ failure. Stromedix Inc. was acquired ... hot and cold jugWebCMO Stromedix Inc. (Private Biotech Company developing novel anti-fibrotic therapeutics) Goals: COO/CEO position for early stage biotech company development novel … psychotherapie in 12349 berlinWebFeb 14, 2012 · Biogen Idec Inc. said Tuesday it will pay $75 million upfront and as much as $487.5 million in future payments to acquire closely held biotechnology company Stromedix Inc., which is working on a ... hot and cold katy perry kidz bopWebThe Weston, MA-based biotech power has bought nearby Stromedix, whose lead fibrosis drug STX-100 was licensed from Biogen. The deal Biogen Idec ($BIIB) has scooped up a … psychotherapie impuls.deWebCMO Stromedix Inc. (Private Biotech Company developing novel anti-fibrotic therapeutics) Goals: COO/CEO position for early stage biotech company development novel therapeutics for unmet medical needs psychotherapie in bayreuth